![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
The companies will jointly develop SI-613 in China for knee osteoarthritis. After obtaining approval, Seikagaku will supply products to Eisai, and Eisai will be responsible for distribution.
Lead Product(s): Diclofenac conjugated sodium hyaluronate
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 01, 2020